Latest News
Synlogic begins dosing in Phase I trial of SYNB1020 to treat hyperammonemia
Synlogic has begun dosing healthy volunteers in its Phase I clinical trial of SYNB1020 for the treatment of hyperammonemia associated with diseases such as urea cycle disorders (UCD) and...
Novartis reports favourable data from Phase III extension trial of Cosentyx for AS
Galera enrols last patient in Phase IIb trial of GC4419 to treat oral mucositis
US-based biotechnology company Galera Therapeutics has concluded enrolment in the Phase IIb clinical trial of GC4419 for the treatment of oral mucositis (OM) in patients with head and neck...
Xencor reports interim positive results from Phase II trial of XmAb5871 for IgG4-RD
Biopharmaceutical firm Xencor has reported interim positive results from the Phase II clinical trial of XmAb5871 for the treatment of patients with active IgG4-Related Disease...
RedHill Biopharma commences Phase III trial of RHB-105 to treat H. pylori infection
Helsinn and MEI begin dosing in Phase II combination trial to treat MDS
Swiss pharmaceutical group Helsinn and US-based oncology firm MEI Pharma have begun dosing patients in a Phase II clinical trial of pracinostat and azacitidine combination for the treatment...
Janssen reports positive long-term results from Phase III trial of sirukumab for RA
Janssen-Cilag International (Janssen) has reported positive long-term results from the Phase III SIRROUND-T clinical trial of sirukumab to treat patients with rheumatoid arthritis...
Modra Pharma starts enrolment in Phase II trial of modraDoc006/r for prostate cancer
Netherlands-based oncology drugs developer Modra Pharmaceuticals has started patient enrolment in a Phase II clinical trial of modraDoc006/r to treat patients with metastatic...
Threshold Pharma begins dosing of cancer drugs evofosfamide and ipilimumab in Phase I trial
US-based biopharmaceutical firm Threshold Pharmaceuticals has begun dosing patients in a Phase I clinical trial of evofosfamide in combination with ipilimumab to treat various...
Boehringer and Lilly to assess empagliflozin for chronic kidney disease
Boehringer Ingelheim, in collaboration with Eli Lilly and Company, is set to evaluate empagliflozin in a new clinical outcomes trial to treat patients suffering from chronic kidney...
TiGenix initiates Phase III trial of Cx601 to treat perianal fistulas
Belgium-based biopharmaceutical firm TiGenix has marked the initiation of a Phase III clinical trial of Cx601 for the treatment of complex perianal fistulas in Crohn's disease patients with...
Janssen reports positive results from CANVAS programme of canagliflozin
Seres begins Phase III trial of SER-109 to treat recurrent C. difficile infection
US-based microbiome therapeutics developer Seres Therapeutics has begun a Phase III clinical trial of SER-109 for the treatment of patients suffering from multiple recurrent clostridium...
Sanofi and Regeneron’s two Phase IIIb/IV trials of alirocumab meet primary endpoint
Sanofi and Regeneron Pharmaceuticals have reported positive results from the Phase IIIb/IV DM-INSULIN and DM-DYSLIPIDEMIA clinical trials of Praluent (alirocumab) to treat patients with...
GSK and MMV report positive headline results from two Phase III trials of tafenoquine
Merck and Pfizer report positive results from two Phase III trials of ertugliflozin
Inovio initiates Phase III trial of VGX-3100 to treat HPV-related cervical pre-cancer
Inovio Pharmaceuticals has initiated its Phase III REVEAL clinical programme of VGX-3100 for the treatment of cervical dysplasia associated with human papillomavirus (HPV), following a...
Lexicon’s Phase III trial of sotagliflozin for type 1 diabetes meets primary endpoint
US-based biopharmaceutical firm Lexicon Pharmaceuticals has reported positive top-line results from the Phase III inTandem3 clinical trial of sotagliflozin to treat type 1 diabetes patients on...
Aveo Oncology’s tivozanib enters Phase II part of TiNivo trial for RCC
US-based biopharmaceutical firm Aveo Oncology’s oral drug candidate tivozanib has advanced into the Phase II part of the Phase I/II TiNivo clinical trial to treat advanced renal cell carcinoma...
Alkermes commences Phase III trial of ALKS 3831 in young adults with schizophrenia
Irish biopharmaceutical firm Alkermes has commenced a supportive Phase III ENLIGHTEN-Early clinical trial of ALKS 3831 in young adults with schizophrenia, schizophreniform or bipolar I...
